Lucid Diagnostics (LUCD) said late Tuesday it plans an underwritten public offering of its shares.
The company said it also plans to grant its underwriters a 30-day option to buy additional shares.
Proceeds will be used for working capital and general corporate purposes, Lucid said.
Shares were down over 11% during after-hours trading.